Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EBITDA (2016 - 2025)

Historic EBITDA for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to -$133272.0.

  • Pharma-Bio Serv's EBITDA rose 1353.27% to -$133272.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$637662.0, marking a year-over-year increase of 5047.62%. This contributed to the annual value of -$637662.0 for FY2025, which is 5047.62% up from last year.
  • According to the latest figures from Q4 2025, Pharma-Bio Serv's EBITDA is -$133272.0, which was up 1353.27% from -$313877.0 recorded in Q3 2025.
  • In the past 5 years, Pharma-Bio Serv's EBITDA ranged from a high of $460466.0 in Q3 2023 and a low of -$4.8 million during Q4 2021
  • For the 5-year period, Pharma-Bio Serv's EBITDA averaged around -$174329.4, with its median value being $58598.5 (2022).
  • In the last 5 years, Pharma-Bio Serv's EBITDA crashed by 326258.49% in 2021 and then skyrocketed by 10352.14% in 2022.
  • Quarter analysis of 5 years shows Pharma-Bio Serv's EBITDA stood at -$4.8 million in 2021, then soared by 103.52% to $168962.0 in 2022, then tumbled by 130.64% to -$51765.0 in 2023, then tumbled by 197.75% to -$154130.0 in 2024, then increased by 13.53% to -$133272.0 in 2025.
  • Its last three reported values are -$133272.0 in Q4 2025, -$313877.0 for Q3 2025, and -$98322.0 during Q2 2025.